{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:51:13Z","timestamp":1790927473501,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The presence of pulmonary hypertension (PH) significantly worsens outcomes in patients with advanced sarcoidosis, but its optimal management is unknown. We aimed to characterize a large sarcoidosis-associated pulmonary hypertension (SAPH) cohort to better understand patient characteristics, clinical outcomes, and management strategies including treatment with PH therapies. Patients at Duke University Medical Center with biopsy-proven sarcoidosis and SAPH confirmed by right heart catheterization (RHC) were identified from 1990\u20132010. Subjects were followed for up to 11 years and assessed for differences by treatment strategy for their SAPH, including those who were not treated with PH-specific therapies. Our primary outcomes of interest were change in 6-minute walk distance (6MWD) and change in N-terminal pro-brain natriuretic peptide (NT-proBNP) by after therapy. We included 95 patients (76% women, 86% African American) with SAPH. Overall, 70% of patients had stage IV pulmonary sarcoidosis, and 77% had functional class III\/IV symptoms. Median NT-proBNP value was elevated (910 pg\/mL), and right ventricular dysfunction was moderate\/severe in 55% of patients. Median values for mean pulmonary artery pressure (49 mmHg) and pulmonary vascular resistance (8.5 Woods units) were consistent with severe pulmonary hypertension. The mortality rate over median 3-year follow-up was 32%. Those who experienced a clinical event and those who did not had similar overall echocardiographic findings, hemodynamics, 6MWD and NT-proBNP at baseline, and unadjusted analysis showed that only follow-up NT-proBNP was associated with all-cause hospitalization or mortality. A sign test to evaluate the difference between NT-Pro-BNP before and after PH therapy produced evidence that a significant difference existed between the median pre- and post-NT-Pro-BNP (\u2212387.0 (IQR: \u22121373.0-109), p\u2009=\u20090.0495). Use of PH-specific therapy may be helpful in selected patients with SAPH and pre-capillary pulmonary vascular disease. Prospective trials are needed to characterize responses to PH-specific therapy in this subset of patients with SAPH.<\/jats:p>","DOI":"10.1038\/s41598-019-40030-w","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T11:02:58Z","timestamp":1552302178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-8916","authenticated-orcid":false,"given":"Kishan S.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Dahhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Nicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ruopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina-Maria","family":"Pomann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor F.","family":"Tapson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-5040","authenticated-orcid":false,"given":"Sudarshan","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"40030_CR1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1378\/chest.14-2546","volume":"148","author":"CA Bonham","year":"2015","unstructured":"Bonham, C. A., Oldham, J. M., Gomberg-Maitland, M. & Vij, R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 148, 1055\u20131062, https:\/\/doi.org\/10.1378\/chest.14-2546 (2015).","journal-title":"Chest"},{"key":"40030_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1378\/chest.128.3.1483","volume":"128","author":"R Sulica","year":"2005","unstructured":"Sulica, R. et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128, 1483\u20131489, https:\/\/doi.org\/10.1378\/chest.128.3.1483 (2005).","journal-title":"Chest"},{"key":"40030_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1183\/09031936.05.00083404","volume":"25","author":"AF Shorr","year":"2005","unstructured":"Shorr, A. F., Helman, D. L., Davies, D. B. & Nathan, S. D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. The European respiratory journal 25, 783\u2013788, https:\/\/doi.org\/10.1183\/09031936.05.00083404 (2005).","journal-title":"The European respiratory journal"},{"key":"40030_CR4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1378\/chest.129.5.1246","volume":"129","author":"T Handa","year":"2006","unstructured":"Handa, T. et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129, 1246\u20131252, https:\/\/doi.org\/10.1378\/chest.129.5.1246 (2006).","journal-title":"Chest"},{"key":"40030_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.chest.2016.08.002","volume":"151","author":"OA Shlobin","year":"2017","unstructured":"Shlobin, O. A., Brown, A. W. & Nathan, S. D. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest 151, 204\u2013214, https:\/\/doi.org\/10.1016\/j.chest.2016.08.002 (2017).","journal-title":"Chest"},{"key":"40030_CR6","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau, G. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62, D34\u201341, https:\/\/doi.org\/10.1016\/j.jacc.2013.10.029 (2013).","journal-title":"J Am Coll Cardiol"},{"key":"40030_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S0012-3692(15)37649-2","volume":"124","author":"AF Shorr","year":"2003","unstructured":"Shorr, A. F., Davies, D. B. & Nathan, S. D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 124, 922\u2013928 (2003).","journal-title":"Chest"},{"key":"40030_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1183\/09031936.00175511","volume":"39","author":"OA Shlobin","year":"2012","unstructured":"Shlobin, O. A. & Nathan, S. D. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. The European respiratory journal 39, 1520\u20131533, https:\/\/doi.org\/10.1183\/09031936.00175511 (2012).","journal-title":"The European respiratory journal"},{"key":"40030_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1378\/chest.120.3.866","volume":"120","author":"IR Preston","year":"2001","unstructured":"Preston, I. R. et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 120, 866\u2013872 (2001).","journal-title":"Chest"},{"key":"40030_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.amjcard.2012.09.031","volume":"111","author":"D Dobarro","year":"2013","unstructured":"Dobarro, D. et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. The American journal of cardiology 111, 278\u2013285, https:\/\/doi.org\/10.1016\/j.amjcard.2012.09.031 (2013).","journal-title":"The American journal of cardiology"},{"key":"40030_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1378\/chest.13-1766","volume":"145","author":"RP Baughman","year":"2014","unstructured":"Baughman, R. P. et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 145, 810\u2013817, https:\/\/doi.org\/10.1378\/chest.13-1766 (2014).","journal-title":"Chest"},{"key":"40030_CR12","first-page":"110","volume":"26","author":"RP Baughman","year":"2009","unstructured":"Baughman, R. P. et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG\/World Association of Sarcoidosis and Other Granulomatous Disorders 26, 110\u2013120 (2009).","journal-title":"Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG \/ World Association of Sarcoidosis and Other Granulomatous Disorders"},{"key":"40030_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1086\/688775","volume":"6","author":"HJ Ford","year":"2016","unstructured":"Ford, H. J., Baughman, R. P., Aris, R., Engel, P. & Donohue, J. F. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ 6, 557\u2013562, https:\/\/doi.org\/10.1086\/688775 (2016).","journal-title":"Pulm Circ"},{"key":"40030_CR14","doi-asserted-by":"publisher","unstructured":"Boucly, A. et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. The European respiratory journal 50, https:\/\/doi.org\/10.1183\/13993003.00465-2017 (2017).","DOI":"10.1183\/13993003.00465-2017"},{"key":"40030_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2018.04.015","volume":"139","author":"RP Baughman","year":"2018","unstructured":"Baughman, R. P. et al. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respir Med 139, 72\u201378, https:\/\/doi.org\/10.1016\/j.rmed.2018.04.015 (2018).","journal-title":"Respir Med"},{"key":"40030_CR16","doi-asserted-by":"publisher","unstructured":"Baughman, R. P. & Shlobin, O. A. Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far. The European respiratory journal 50, https:\/\/doi.org\/10.1183\/13993003.01725-2017 (2017).","DOI":"10.1183\/13993003.01725-2017"},{"key":"40030_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jbi.2010.11.008","volume":"44","author":"MM Horvath","year":"2011","unstructured":"Horvath, M. M. et al. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. J Biomed Inform 44, 266\u2013276, https:\/\/doi.org\/10.1016\/j.jbi.2010.11.008 (2011).","journal-title":"J Biomed Inform"},{"key":"40030_CR18","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1183\/09031936.00187410","volume":"38","author":"A Nardi","year":"2011","unstructured":"Nardi, A. et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. The European respiratory journal 38, 1368\u20131373, https:\/\/doi.org\/10.1183\/09031936.00187410 (2011).","journal-title":"The European respiratory journal"},{"key":"40030_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1378\/chest.130.5.1481","volume":"130","author":"KA Fisher","year":"2006","unstructured":"Fisher, K. A. et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 130, 1481\u20131488, https:\/\/doi.org\/10.1378\/chest.130.5.1481 (2006).","journal-title":"Chest"},{"key":"40030_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.healun.2007.11.576","volume":"27","author":"N Milman","year":"2008","unstructured":"Milman, N. et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 27, 329\u2013334, https:\/\/doi.org\/10.1016\/j.healun.2007.11.576 (2008).","journal-title":"The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation"},{"key":"40030_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1378\/chest.08-1881","volume":"135","author":"CF Barnett","year":"2009","unstructured":"Barnett, C. F. et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 135, 1455\u20131461, https:\/\/doi.org\/10.1378\/chest.08-1881 (2009).","journal-title":"Chest"},{"key":"40030_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1378\/chest.09-2002","volume":"138","author":"RP Baughman","year":"2010","unstructured":"Baughman, R. P., Engel, P. J., Taylor, L. & Lower, E. E. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 138, 1078\u20131085, https:\/\/doi.org\/10.1378\/chest.09-2002 (2010).","journal-title":"Chest"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40030-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:29:22Z","timestamp":1671262162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40030-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40030"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40030-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"24 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sudarshan Rajagopal (Sudarshan.rajagopal@duke.edu): Consulted for United Therapeutics, Gilead Sciences and Bayer Sciences. Research funded by United Therapeutics and Gilead Sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4061"}}